Ra Capital Management, L.P. - Apr 2, 2024 Form 4 Insider Report for Boundless Bio, Inc. (BOLD)

Role
10%+ Owner
Signature
/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
Stock symbol
BOLD
Transactions as of
Apr 2, 2024
Transactions value $
$5,000,000
Form type
4
Date filed
4/4/2024, 04:15 PM
Previous filing
Mar 29, 2024
Next filing
Apr 15, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BOLD Common Stock Conversion of derivative security +1.59M 1.59M Apr 2, 2024 See footnotes F1, F2, F3
transaction BOLD Common Stock Purchase $4.75M +297K +18.7% $16.00* 1.88M Apr 2, 2024 See footnotes F2, F3
transaction BOLD Common Stock Conversion of derivative security +280K 280K Apr 2, 2024 See footnotes F1, F3, F4
transaction BOLD Common Stock Purchase $250K +15.6K +5.58% $16.00* 296K Apr 2, 2024 See footnotes F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BOLD Series B Preferred Stock Conversion of derivative security $0 -17M -100% $0.00* 0 Apr 2, 2024 Common Stock 872K See footnotes F1, F2, F3
transaction BOLD Series B Preferred Stock Conversion of derivative security $0 -3M -100% $0.00* 0 Apr 2, 2024 Common Stock 154K See footnotes F1, F3, F4
transaction BOLD Series C Preferred Stock Conversion of derivative security $0 -14M -100% $0.00* 0 Apr 2, 2024 Common Stock 716K See footnotes F1, F2, F3
transaction BOLD Series C Preferred Stock Conversion of derivative security $0 -2.46M -100% $0.00* 0 Apr 2, 2024 Common Stock 126K See footnotes F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Ra Capital Management, L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 On April 2, 2024, each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a 19.5-for-1 basis immediately prior to the closing of the Issuer's initial public offering. The shares of Series B Preferred Stock and Series C Preferred Stock had no expiration date.
F2 Held directly by RA Capital Healthcare Fund, L.P. (the "Fund").
F3 RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
F4 Held directly by the Nexus Fund II.